NASDAQ:ETNB89bio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding 89bio Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $31.25 +1.24 (+4.13 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$30.23Now: $31.25▼$33.3650-Day Range$19.93MA: $28.73▼$34.8452-Week Range$14.00Now: $31.25▼$47.25Volume53,669 shsAverage Volume55,647 shsMarket Capitalization$405.94 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 that is being developed for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.33, 89bio has a potential upside of 57.9% from its current price of $31.25.Amount of Analyst Coverage89bio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform Votes89bio has received 35 “outperform” votes. (Add your “outperform” vote.)Underperform Votes89bio has received 29 “underperform” votes. (Add your “underperform” vote.)Community Sentiment89bio has received 54.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about 89bio and other stocks. Vote “Outperform” if you believe ETNB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ETNB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,562,475.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 18.10% of the stock of 89bio is held by insiders.Percentage Held by Institutions82.37% of the stock of 89bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($3.59) to ($4.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.03 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ETNB Previous Symbol CUSIPN/A CIKN/A Webwww.89bio.com Phone415-500-4614Debt Debt-to-Equity RatioN/A Current Ratio11.23 Quick Ratio11.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book4.52Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees13 Outstanding Shares12,990,000Market Cap$405.94 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable $31.25 +1.24 (+4.13 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ETNB News and Ratings via Email Sign-up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. 89bio (NASDAQ:ETNB) Frequently Asked Questions How has 89bio's stock been impacted by COVID-19 (Coronavirus)? 89bio's stock was trading at $33.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ETNB shares have decreased by 6.9% and is now trading at $31.25. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of 89bio? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for 89bio. When is 89bio's next earnings date? 89bio is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for 89bio. How were 89bio's earnings last quarter? 89bio (NASDAQ:ETNB) posted its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.10. View 89bio's earnings history. What price target have analysts set for ETNB? 7 brokers have issued 12 month price targets for 89bio's stock. Their forecasts range from $33.00 to $60.00. On average, they expect 89bio's share price to reach $49.33 in the next year. This suggests a possible upside of 57.9% from the stock's current price. View analysts' price targets for 89bio. Has 89bio been receiving favorable news coverage? News coverage about ETNB stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. 89bio earned a daily sentiment score of -4.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about 89bio. Are investors shorting 89bio? 89bio saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 136,000 shares, a decrease of 82.4% from the June 30th total of 774,200 shares. Based on an average trading volume of 92,100 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.1% of the shares of the company are short sold. View 89bio's Short Interest. Who are some of 89bio's key competitors? Some companies that are related to 89bio include Madrigal Pharmaceuticals (MDGL), Corcept Therapeutics (CORT), Intercept Pharmaceuticals (ICPT), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), INDIVIOR PLC/S (INVVY), Y-mAbs Therapeutics (YMAB), Revance Therapeutics (RVNC), MacroGenics (MGNX), Rocket Pharmaceuticals (RCKT), Akebia Therapeutics (AKBA), Myovant Sciences (MYOV), Portola Pharmaceuticals (PTLA) and Zymeworks (ZYME). View all competitors. What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Aurinia Pharmaceuticals (AUPH), Crispr Therapeutics (CRSP), Pfizer (PFE), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Aptose Biosciences (APTO), Ardelyx (ARDX), Athenex (ATNX), Anavex Life Sciences (AVXL) and Blueprint Medicines (BPMC). Who are 89bio's key executives? 89bio's management team includes the following people: Mr. Rohan Palekar, CEO & Director (Age 53)Mr. Ryan Stephen Martins, Chief Financial Officer (Age 42)Mr. Ram Waisbourd, COO & Chief Bus. Officer (Age 52)Mr. Quoc Le-Nguyen, Chief Technical Operations Officer & Head of Quality (Age 51)Dr. Hank Mansbach M.D., Chief Medical Officer (Age 54) When did 89bio IPO? (ETNB) raised $70 million in an initial public offering (IPO) on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. What is 89bio's stock symbol? 89bio trades on the NASDAQ under the ticker symbol "ETNB." How do I buy shares of 89bio? Shares of ETNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is 89bio's stock price today? One share of ETNB stock can currently be purchased for approximately $31.25. How big of a company is 89bio? 89bio has a market capitalization of $405.94 million. The company earns $-57,420,000.00 in net income (profit) each year or ($24.49) on an earnings per share basis. 89bio employs 13 workers across the globe. What is 89bio's official website? The official website for 89bio is www.89bio.com. How can I contact 89bio? 89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-500-4614 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
